Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) plummeted 5.78% in after-hours trading on Monday, October 29, 2024, following the company's third-quarter 2024 financial results and pipeline updates.
The biopharmaceutical company reported a narrower net loss of $93.6 million for the quarter, compared to a net loss of $201.6 million in the same period last year. However, the market reacted negatively to Sage's decision to halt further development of its investigational drug zuranolone as a treatment for major depressive disorder (MDD) in the U.S.
Sage and its partner Biogen had previously received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for zuranolone in MDD. The companies concluded that the significant additional investment and time required for further studies made the MDD program commercially unviable in the U.S. market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。